A 60-year-old man involved in a high-speed collision with a hay wagon was admitted with multiple trauma. He developed life-threatening invasive musculo-cutaneous zygomycosis caused by Rhizopus species, which is found in soil from cultivated land and woodland. A high index of suspicion given the nature of the injury, aggressive surgical debridement and appropriate anti-fungal therapy prevented a fatal outcome.
de MolPMeisJFGM. Disseminated Rhizopus microsporus infection in a patient on oral corticosteroid treatment. Neth J Med2009;67: 25–28.
2.
RodenMMZaoutisTEBuchananWL. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis2005;41: 634–53.
3.
SpellbergBEdwardsJIbrahimA. Novel perspectives on mucormycosis: pathophysiology, presentation and management. Clin Microbiol Rev2005;18: 556–69.
4.
McBrideRACorsonJMDamminGJ. Mucormycosis: Two cases of disseminated disease with cultural identification of rhizopus; review of literature. Am J Med1960;28: 832–46.
5.
DalyALVelazquezLABradleySFKauffmanCA. Mucormycosis: association with desferoxamine therapy. Am J Med1989;87: 468–71.
6.
RibesJAVanover-SamsCLBakerDJ. Zygomycetes in human disease. Clin Microbiol Rev2000;13: 236–301.
7.
KontogiorgiMFlorosIKoroneosA. Fatal post-traumatic zygomycosis in an immunocompetent young patient. J Med Microbiol2007;56: 1243–45.
8.
SkiadaAPaganoLGrollA. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect ePub ahead of print. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2010.03456.x/abstract. Accessed 12th March 2011.
9.
El DeebYAl SoubHAlmaslamaniM. Post-traumatic cutaneous mucormycosis in an immunocompetent patient. Ann Saudi Med2005;25: 343–45.
10.
GreenbergRNMullaneKvan BurikJ-AH. Posaconazole as salvage therapy for Zygomycosis. Antimicrob Agents Chemother2006;50: 126–33.
11.
SimitsopoulouMRoilidesEMaloukouA. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes. Mycoses2008;51: 147–54.
